Abuse-Deterrent Technology Platform
With the growing problem of prescription drug abuse, we have created two distinct drug delivery systems, each with novel abuse-deterrent features and the ability to control the release profile of the active pharmaceutical ingredient, or API. Using our proprietary technology platform, we have developed a pipeline of clinical-stage, opioid-based product candidates in tablet form that are specifically designed to deter abuse by physical and chemical manipulation while also providing the ability to tailor the release of the API. Egalet’s lead product candidates, Egalet-001 and Egalet 002, are abuse-deterrent, extended-release, oral formulations of commonly prescribed opioids in development for the treatment of moderate to severe pain. Our technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple APIs with similar or different release profiles. In addition to our two clinical-stage product candidates, we are developing a portfolio of preclinical, abuse-deterrent product candidates for the treatment of pain and other conditions.